Alfred Clinical Trials

Alfred Health has more than 700 open trials across 20 clinical disciplines, our clinical trial portfolio is one of the largest in the country.

Clear filter
604 clinical trials found
Clinical trials

STRIVE

A Multicenter, Adaptive, Randomized, Controlled Trial Platform to Evaluate Safety and Efficacy of Strategies and Treatments for Hospitalized Patients with Respiratory and Viral Diseases (NCT05605093)

Currently recruiting

OCEANIC AF

A multicenter, international, randomized, active comparator-controlled, double-blind, double-dummy, parallel-group, 2-arm, Phase 3 study to compare the efficacy and safety of the oral FXIa inhibitor asundexian (BAY 2433334) with apixaban for the prevention of stroke or systemic embolism in male and female participants aged 18 years and older with atrial fibrillation at risk for stroke (NCT05643573)

Currently recruiting

OCEANIC-STROKE

A multicenter, international, randomized, placebo controlled, double-blind, parallel group and event driven Phase 3 study of the oral FXIa inhibitor asundexian (BAY 2433334) for the prevention of ischemic stroke in male and female participants aged 18 years and older after an acute non-cardioembolic ischemic stroke or high-risk TIA (NCT05686070)

Currently recruiting

BG C477 101

A Multicenter, Open-Label, Phase 1a/b First-in-Human Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BG-C477 in Patients with Selected Advanced Solid Tumors (NCT06596473)

Currently recruiting

D7400C00006

A Multicenter, Phase 1, Open-label, Dose-escalation and Expansion Study of AZD0486, a Bispecific Antibody Targeting CD19 in Subjects with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (NCT04594642)

Currently recruiting

TNB486.001

A Multicenter, Phase 1, Open-label, Dose-escalation and Expansion Study of TNB-486, a Bispecific Antibody Targeting CD19 in Subjects with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (NCT04594642)

Currently recruiting

RESOLUTE

A multicenter, randomized, double-blind, chronic-dosing, parallel-group, placebo-controlled phase 3 study to evaluate the efficacy and safety of bendralizumab 100mg in patietns with moderate to very severe chronic obstructive pulmonary disease (COPD) wiht a history of frequent COPD exacerbations and elevated peripheral blood eosinophils. (RESOLUTE) (NCT04053634)

No longer recruiting

MK-4280A-010

A Multicenter, Randomized, Double-Blind, Phase 2, Basket Study of MK-4280A, a Coformulation of Favezelimab (MK-4280) with Pembrolizumab (MK-3475) in Selected Solid Tumors (NCT06036836)

No longer recruiting

SHR3162-III-305

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined with Abiraterone Acetate and Prednisone (AA-P) versus Placebo Combined with AA-P as First-Line Treatment in Patients with Metastatic Castration-Resistant Prostate Cancer (NCT04691804)

No longer recruiting

TAKEDA-LGS-DB

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy, Safety, and Tolerability of Soticlestat as Adjunctive Therapy in Pediatric and Adult Subjects With Lennox-Gastaut Syndrome (LGS) (NCT04938427)

Currently recruiting

TAKEDA-DS-DB

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy, Safety, and Tolerability of Soticlestat as Adjunctive Therapy in Pediatric and Young Adult Subjects With Dravet Syndrome (DS) (NCT04940624)

Currently recruiting

Lavender D346BC00001

A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase III Study to Evaluate the Efficacy and Safety of Anifrolumab in Adults with Chronic and/or Subacute Cutaneous Lupus Erythematosus who are Refractory and/or Intolerant to Antimalarial Therapy (NCT06015737)

Currently recruiting

ANT-007

A multicenter, randomized, open-label, blinded endpoint evaluation, phase 3 study comparing the effect of abelacimab relative to apixaban on venous thromboembolism (VTE) recurrence and bleeding in patients with cancer associated VTE (ASTER) [ANT-007] (NCT05171049)

Currently recruiting

ANT-008

A multicenter, randomized, open-label, blinded endpoint evaluation, phase 3 study comparing the effect of abelacimab relative to dalteparin on venous thromboembolism (VTE) recurrence and bleeding in patients with gastrointestinal (GI)/genitourinary (GU) cancer associated VTE (Magnolia) [ANT-008] (NCT05171075)

Currently recruiting

LIBRETTO-531

A Multicenter, Randomized, Open-label, Phase 3 Trial Comparing LOXO-292 to Physicians Choice of Cabozantinib or Vandetanib in Patients with Progressive, Advanced, Kinase Inhibitor Naïve, RET-Mutant Medullary Thyroid Cancer (LIBRETTO-531) (NCT04211337)

Currently recruiting

M20-350

A Multicenter, Single-Arm Prospective Study to Evaluate Safety and Efficacy of GLE/PIB 8-Week Treatment in Adults and Adolescents with Acute Hepatitis C Virus (HCV) Infection (NCT04903626)

Currently recruiting

CALM-ICU

A multicentre, cluster randomised, double cross over pragmatic clinical trial comparing the safety and efficacy of enteral olanzapine with quetiapine in critically ill patients with hyperactive delirium (CALM-ICU). (ACTRN12622001532796)

Recently completed/closed

MajesTEC-2

A Multicentre, multi-arm, non-randomised, Phase 1b dose escalation Study of Teclistamab for newly diagnosed or relapsed/refractory MM. (NCT03145181)

No longer recruiting

Integrum

A multicentre, multinational, cohort long-term post-market Clinical [PMCF] follow-up of the safety and efficacy of the Osseo anchored Prostheses for the Rehabilitation of Amputees [OPRA] implant system when used for trans humeral implantation in amputee patients (NCT06753110)

Currently recruiting

COALITION

A multicentre, parallel arm, open-label trial of frontline R-CHOP/Pola-RCHP and glofitamab in younger, higher risk patients with diffuse large B cell lymphoma (DLBCL) (COALITION) (NCT04914741)

No longer recruiting
1 2 3 4 5